How to Get Evenity (Romosozumab) in New York

What Romosozumab Does and Why Prescribers Use It

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab simultaneously increases new bone formation and reduces bone resorption, a dual mechanism no other osteoporosis drug replicates.

The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple fracture risk factors, or failure of other osteoporosis therapies 1. In the FRAME trial (N=7,180), romosozumab reduced new vertebral fractures by 73% compared to placebo at 12 months 2. The ARCH trial (N=4,093) compared romosozumab to alendronate and demonstrated a 48% lower risk of new vertebral fracture and a 38% lower risk of clinical fracture at 24 months 3. These are large effect sizes.

The 2020 AACE/ACE Clinical Practice Guidelines for postmenopausal osteoporosis recommend romosozumab as first-line therapy for patients classified as "very high fracture risk" 4. Dr. Felicia Cosman, professor of medicine at Columbia University, has stated: "Romosozumab represents a true anabolic option for the skeleton. Starting with an anabolic agent and then transitioning to an antiresorptive may be the most effective sequence we have" 2.

The drug carries an FDA black box warning for increased risk of myocardial infarction, stroke, and cardiovascular death. It should not be prescribed to patients who have experienced a cardiovascular event within the preceding 12 months 1.

Who Qualifies for Evenity in New York

The prescribing criteria in New York mirror the FDA-approved indication, but insurers add their own clinical thresholds. Most New York commercial plans and Medicaid require all three: a confirmed diagnosis of postmenopausal osteoporosis, a DEXA T-score of -2.5 or lower at the spine or hip, and documented high fracture risk.

High fracture risk can be established by a prior fragility fracture (vertebral, hip, or proximal humerus), a FRAX 10-year probability of major osteoporotic fracture exceeding 20%, or failure of at least one prior osteoporosis therapy such as a bisphosphonate or denosumab 4. "Failure" typically means a new fracture on therapy, continued bone loss on DEXA, or documented intolerance.

New York Medicaid covers Evenity with prior authorization for severe osteoporosis. The state Medicaid formulary requires documentation that the patient meets high-risk criteria and that the prescriber has considered cardiovascular contraindications 5. Patients with a history of MI, stroke, or uncontrolled hypertension within 12 months are not candidates.

Male osteoporosis is currently off-label for romosozumab, though studies are ongoing. New York prescribers may consider off-label use in men with very high fracture risk, but insurance coverage is unlikely without specific policy exceptions.

How to Get an Evenity Prescription in New York

Getting Evenity in New York follows a predictable clinical pathway. Here are the steps in order.

Step 1: Consultation with a qualified prescriber. Schedule with an endocrinologist, rheumatologist, or primary care physician experienced in osteoporosis management. In New York, MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) with prescriptive authority can all prescribe Evenity. NPs in New York have full practice authority as of 2023, meaning they can prescribe independently without physician oversight 6.

Step 2: Baseline DEXA scan and labs. Your provider will order a dual-energy X-ray absorptiometry (DEXA) scan, serum calcium, 25-hydroxyvitamin D, basic metabolic panel, and possibly bone turnover markers such as P1NP and CTX.

Step 3: Cardiovascular risk screening. Because of the black box warning, your provider must assess cardiovascular risk. This includes reviewing blood pressure history, lipid panels, and any cardiac events within the past year 1.

Step 4: Prior authorization submission. Your provider's office submits clinical documentation to your insurer. This process takes 5 to 14 business days for most New York commercial plans.

Step 5: Specialty pharmacy fulfillment. Evenity is dispensed through specialty pharmacies. The medication ships to your provider's office or, in some cases, directly to you with instructions for administration.

Step 6: Monthly injections begin. Each dose is two subcutaneous injections of 105 mg each (total 210 mg), administered in the abdomen, thigh, or upper arm. Most patients receive injections in a clinical setting.

Telehealth Options for Evenity in New York

New York permits telehealth prescribing of Evenity. That means the initial consultation, cardiovascular risk assessment, and ongoing monitoring visits can happen by video or phone under New York Education Law Section 6524-a and subsequent telehealth expansions.

A telehealth provider can review your existing DEXA results, order labs at a local facility, and submit the prior authorization. The physical injections still require an in-person visit, whether at a local infusion center, specialty clinic, or your primary care office. Some patients self-administer after training, though most insurance plans prefer clinical administration for a drug at this price point.

Telehealth consultations typically cost between $75 and $200 for the initial visit, depending on the platform and provider. Follow-up visits tend to be less. For New York Medicaid recipients, telehealth visits are covered at the same rate as in-person visits. The 2023 Endocrine Society position statement notes: "Telehealth has the potential to expand access to endocrine specialists in underserved areas, and osteoporosis management, including treatment initiation, is well suited to virtual care models" 7.

For patients in rural areas of upstate New York, where endocrinologists may be more than 60 miles away, telehealth removes a real barrier. The consultation, lab review, PA submission, and follow-up monitoring can all be done remotely. Only the injection itself needs proximity.

Labs and Screening Before Starting Evenity

Your prescriber will order a specific panel before the first injection. No exceptions.

DEXA scan: This is the foundation. You need a T-score at the lumbar spine, femoral neck, or total hip. The scan must be recent, typically within the past 24 months, though many insurers want results from the past 12 months 4.

Serum calcium: Romosozumab can cause hypocalcemia. Calcium levels must be corrected before starting treatment. If serum calcium is low, your provider will prescribe supplementation and recheck before initiating Evenity 1.

25-hydroxyvitamin D: Vitamin D deficiency is common among osteoporosis patients and must be corrected. Levels below 30 ng/mL typically prompt repletion with 50 to 000 IU weekly for 8 to 12 weeks before treatment begins 8.

Basic metabolic panel: Kidney function matters. Severe renal impairment does not require dose adjustment for romosozumab, but clinicians need a baseline for monitoring 1.

Bone turnover markers (optional but recommended): P1NP (procollagen type 1 N-terminal propeptide) reflects bone formation. CTX (C-terminal telopeptide) reflects resorption. Baseline values help your provider track treatment response. P1NP typically rises 100% to 150% within the first month of romosozumab, a sign the drug is working 2.

Cardiovascular screening: A cardiovascular risk assessment using the ACC/AHA pooled cohort equations or ASCVD risk calculator is standard. EKGs or stress testing may be ordered for borderline patients 5.

Prior Authorization for Evenity in New York

Almost every insurer in New York requires prior authorization for Evenity. The drug's wholesale acquisition cost is approximately $1,825 per monthly dose, totaling roughly $21,900 for the full 12-month course. Insurers want documentation before approving that spend.

What PA documentation requires in New York:

• DEXA results showing a T-score of -2.5 or lower at any measured site
• Clinical evidence of high fracture risk (prior fracture, FRAX score, or falls history)
• Documentation that cardiovascular risk has been assessed and the patient has no MI or stroke within 12 months
• For some plans, documentation that the patient has tried and failed (or is intolerant of) at least one bisphosphonate
• ICD-10 codes: M80.x (osteoporosis with pathological fracture) or M81.0 (age-related osteoporosis without fracture)

New York Medicaid processes PAs through the state's preferred drug program. Turnaround is typically 7 to 10 business days. Commercial plans like Empire BlueCross BlueShield, Aetna, and UnitedHealthcare in New York average 5 to 14 business days 9. If denied, your provider can submit a peer-to-peer review or formal appeal. First-line denial rates for Evenity run between 15% and 30% at many commercial plans, often due to incomplete documentation rather than clinical ineligibility.

The Endocrine Society's 2020 guidelines support romosozumab as initial therapy in very high-risk patients, which can strengthen an appeal: "For patients at very high fracture risk, anabolic therapy should be considered as initial treatment rather than reserving it for after antiresorptive failure" 10.

Where to Fill an Evenity Prescription in New York

Evenity is a specialty medication. You will not find it at a standard retail pharmacy. It is distributed through specialty pharmacies that maintain cold-chain storage and handle the specific shipping requirements for biologic drugs.

Major specialty pharmacies operating in New York include Accredo (Express Scripts), CVS Specialty, Optum Specialty, and BriovaRx. Your insurer typically mandates which specialty pharmacy you use. The medication ships in prefilled syringes that must be stored at 2°C to 8°C (36°F to 46°F) and protected from light 1.

New York-licensed 503A compounding pharmacies can compound certain formulations under strict New York State Board of Pharmacy oversight. For romosozumab specifically, compounding is limited because it is a monoclonal antibody, a complex biologic that cannot be replicated through traditional compounding methods. Patients should expect to receive the brand-name Evenity product through a specialty pharmacy, not a compounded version.

Delivery timelines after PA approval typically range from 3 to 7 business days for the first shipment. Subsequent monthly shipments are coordinated with your injection schedule. Most specialty pharmacies assign a dedicated care coordinator who schedules refills and monitors adherence throughout the 12-dose course.

Cost, Insurance, and Patient Assistance

Evenity costs approximately $21,900 for the full 12-month treatment course at wholesale acquisition pricing. Out-of-pocket costs vary widely based on insurance.

Medicare Part B: Evenity administered in a physician's office is covered under Part B with standard 20% coinsurance after the deductible. For a patient without supplemental coverage, that could mean $3,000 to $4,000 out of pocket over 12 months 9.

New York Medicaid: Covered with prior authorization. Copays are minimal, often $0 to $3 per dose for Medicaid recipients.

Commercial insurance: Most major plans in New York cover Evenity on specialty tiers. Copays or coinsurance range from $50 to $500 per month depending on your plan's specialty drug tier and out-of-pocket maximum.

Amgen Assist 360: Amgen offers a patient support program that includes copay assistance for commercially insured patients (reducing out-of-pocket costs to as low as $5 per month) and free drug programs for uninsured or underinsured patients who meet income criteria 11. Patients with government insurance (Medicare, Medicaid, Tricare) are not eligible for copay cards but may qualify for other assistance.

New York EPIC (Elderly Pharmaceutical Insurance Coverage): New York residents aged 65 and older with annual incomes up to $75,000 (single) or $100,000 (married) may qualify for additional prescription drug coverage through the state's EPIC program, which can offset Part D costs.

What to Expect During 12 Months of Treatment

The treatment course is fixed. Twelve monthly injections, no more. Romosozumab's anabolic window closes after 12 months as the sclerostin pathway adapts and bone formation rates return toward baseline 2.

Injection experience: Each visit involves two subcutaneous injections administered sequentially, one 105 mg prefilled syringe in one site and the second in a different site (abdomen, thigh, or upper arm). The injection takes about 30 seconds per syringe. Most patients report mild injection-site reactions (redness, tenderness) that resolve within 48 hours 1.

Common side effects in the FRAME and ARCH trials: Arthralgia (12.4%), headache (5.7%), injection-site reactions (5.2%), and nasopharyngitis (13.6%) 2 3.

Monitoring during treatment: Your provider should recheck serum calcium at 2 to 4 weeks after the first dose and periodically thereafter. Bone turnover markers (P1NP, CTX) at months 3 and 6 help confirm response. A follow-up DEXA at 12 months documents bone density gains. In FRAME, romosozumab produced a 13.3% increase in lumbar spine BMD and a 6.9% increase at the total hip at 12 months 2.

Cardiovascular monitoring: Report any chest pain, sudden weakness, slurred speech, or shortness of breath immediately. The ARCH trial observed a higher rate of adjudicated serious cardiovascular events in the romosozumab group (2.5%) compared to alendronate (1.9%) over the initial 12-month treatment period 3.

Transitioning After the 12-Dose Course

Stopping romosozumab without follow-on therapy leads to rapid bone loss. This is not optional. The bone density gained during 12 months of treatment begins declining within months if no antiresorptive agent follows.

The FRAME extension data showed that patients who transitioned from romosozumab to denosumab continued to gain bone density, reaching 17.6% at the lumbar spine at 24 months, while those who switched to placebo lost a portion of their gains 2.

Standard post-Evenity sequencing options include:

• Denosumab (Prolia): 60 mg subcutaneous every 6 months. Continues bone density gains. Requires long-term commitment because discontinuation causes rebound bone loss 12.
• Zoledronic acid (Reclast): 5 mg IV infusion once yearly. Consolidates gains and can be used for a defined period (3 to 6 years) with a drug holiday thereafter 13.
• Oral bisphosphonates (alendronate, risedronate): Weekly or monthly tablets. Less effective at maintaining gains than denosumab or zoledronic acid but are lower cost and more accessible.

Dr. E. Michael Lewiecki, director of the New Mexico Clinical Research & Osteoporosis Center, has noted: "The sequence of anabolic first, antiresorptive second produces greater BMD gains and better fracture risk reduction than starting with an antiresorptive alone. Romosozumab followed by denosumab is currently the most potent sequence available" 14.

Your New York provider should have the transition plan established before the first Evenity injection, not at month 11. Discuss sequencing at the initial consultation.